Background and Aims: Serum Irisin may serve as a novel indicator for breast cancer detection and early diagnosis. Irisin may offer therapeutic benefits for breast cancer prevention and treatment. Exercise training modalities have been recently proposed as a complementary treatment strategy in cancer patients. How exactly exercise results in these health benefits is not known. This randomized control trial compared the effect of high intensity interval (HIIT) and continuous moderate training (CMT) on serum Irisin levels in breast cancer patients.
Method: Thirty-nine overweight breast cancer patients were randomly assigned to High Intensity Interval Training (HIIT), Continuous Moderate Training (CMT) and usual care groups. The serum level of Irisin was measured at baseline and twelve weeks of intervention.
Results: The serum level of Irisin in the continuous moderate intensity training group increased significantly at post-intervention. There was a significant difference in Irisin between CMT and HIIT groups at the post-intervention testing.
Conclusion: Twelve weeks of moderate continues intensity exercise increased the circulatory levels of Irisin in breast cancer patients. Continuous moderate training is likely to reduce the inflammation in these patients through the anti-inflammatory function of Irisin.